About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The work of our group is mainly focused on personalized medicine, including chemical-functional stability studies of drugs in individualized preparations to be administered both orally and parenterally, as well as parenteral nutrition; research focused on the evaluation and/or design of population pharmacokinetic/pharmacodynamic (PK/PD) models and the characterization of the pharmacokinetics of certain drugs of therapeutic interest in the general population or in certain population groups; and research focused on pharmacogenetics and pharmacogenomics. Our research is also focused on advanced interventions: drug evaluation studies (effectiveness, safety and economic studies); and mobile health and telepharmacy.
PMID: 37852910 Journal: Journal of Hand Therapy Year: 2023 Reference: J Hand Ther. 2023 Oct 17:S0894-1130(23)00137-0. doi: 10.1016/j.jht.2023.09.012. Impact factor: Publication type: Paper in international publication Authors: Cruz, M J; Espejo, D; Esplugas, Mireia; Fernandez-Noguera, Nuria; Garcia-Elias, Marc; Gomez-Domingo, M R; Lluch, Alex; Llusa-Perez, Manuel; Luengo, O; Munoz, X et al. DOI: 10.1016/j.jht.2023.09.012
PMID: 37858518 Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia H Year: 2023 Reference: Farm Hosp. 2023 Oct 17:S1130-6343(23)00887-5. doi: 10.1016/j.farma.2023.09.006. Impact factor: Publication type: Paper in international publication Authors: Batzler, Anthony; Bianchi, Sevim B; Biernacka, Joanna M; Campany Herrero, David; Canete Ramirez, Carme; Coombes, Brandon J; Cox, Nancy J; Davis, Lea K; Ehinmowo, Michael; Fernandez Polo, Aurora et al. DOI: 10.1016/j.farma.2023.09.006
PMID: 37863310 Journal: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES Year: 2023 Reference: Int J Infect Dis. 2023 Oct 18:S1201-9712(23)00749-X. doi: 10.1016/j.ijid.2023.10.013. Impact factor: Publication type: Paper in international publication Authors: Abu-Zeinah, Ghaith; Adzic-Vukicevic, Tatjana; Aiello, Tommaso Francesco; Ammatuna, Emanuele; Arellano, Elena; Barac, Aleksandra; Bavastro, Martina; Bergantim, Rui; Besson, Caroline; Biernat, Monika M et al. DOI: 10.1016/j.ijid.2023.10.013
PMID: 37964360 Journal: BREAST CANCER RESEARCH Year: 2023 Reference: Breast Cancer Res. 2023 Nov 14;25(1):143. doi: 10.1186/s13058-023-01736-y. Impact factor: Publication type: Paper in international publication Authors: Baulida, Josep; Benitez-Carbante, Maria Isabel; Diaz de Heredia, Cristina; Eyras, Eduardo; Fernandez Ledesma, Berta; Fernandez-Polo, Aurora; Franco-Valls, Hector; Garcia de Herreros, Antonio; Grau Cerrato, Santiago; Iaconcig, Alessandra et al. DOI: 10.1186/s13058-023-01736-y
Within the framework of a clinical trial, the first 3D printed medicine in Europe in the pediatric field will be tested.
